Haemonetics
About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Employees: 3,023
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
424% more call options, than puts
Call options by funds: $16.3M | Put options by funds: $3.11M
23% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 100
16% more capital invested
Capital invested by funds: $3.41B [Q1] → $3.97B (+$558M) [Q2]
3.84% more ownership
Funds ownership: 106.92% [Q1] → 110.76% (+3.84%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
7% less funds holding
Funds holding: 312 [Q1] → 291 (-21) [Q2]
29% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 48
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
Raymond James Andrew Cooper | 43%upside $78 | Outperform Downgraded | 11 Aug 2025 |
Barrington Research Michael Petusky | 57%upside $86 | Outperform Maintained | 8 Aug 2025 |
Mizuho Anthony Petrone | 28%upside $70 | Outperform Maintained | 8 Aug 2025 |
JP Morgan Rohin Patel | 13%upside $62 | Neutral Downgraded | 8 Aug 2025 |
Needham Mike Matson | 24%upside $68 | Buy Maintained | 7 Aug 2025 |
Financial journalist opinion
Based on 10 articles about HAE published over the past 30 days
